BioAge Labs, Inc. (BIOA)
NASDAQ: BIOA · Real-Time Price · USD
8.49
-0.16 (-1.85%)
Sep 11, 2026, 4:00 PM EDT - Market closed
BioAge Labs Employees
As of December 31, 2025, BioAge Labs had 62 total employees, including 60 full-time and 2 part-time employees. The number of employees decreased by 2 or -3.13% compared to the previous year.
Employees
62
Change (1Y)
-2
Growth (1Y)
-3.13%
Revenue / Employee
$167,016
Profits / Employee
-$1,523,613
Market Cap
389.66M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 62 | -2 | -3.13% | 60 | 2 |
| Dec 31, 2024 | 64 | 8 | 14.29% | 62 | 2 |
| Jun 30, 2024 | 60 | - | - | 58 | 2 |
| Mar 31, 2024 | 56 | - | - | 54 | 2 |
| Dec 31, 2023 | 56 | - | - | 54 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Evotec SE | 4,461 |
| Tilray Brands | 3,595 |
| Canopy Growth | 1,128 |
| Aurora Cannabis | 1,028 |
| Emergent BioSolutions | 900 |
| Kamada | 462 |
| Evolus | 353 |
| Anika Therapeutics | 235 |
BIOA News
- 1 day ago - BioAge Labs Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 3 days ago - BioAge Labs Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 4 days ago - BioAge Labs doses first patient in QUELL-DME study - TheFly
- 4 days ago - BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema - GlobeNewsWire
- 10 days ago - BioAge Labs to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - BioAge Labs price target lowered to $20 from $23 at Morgan Stanley - TheFly
- 5 weeks ago - BioAge Labs price target lowered to $21 from $52 at Citi - TheFly
- 5 weeks ago - BioAge Labs reports Q2 EPS (58c), consensus (62c) - TheFly